Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
17
01
2023
accepted:
12
07
2023
medline:
20
10
2023
pubmed:
20
10
2023
entrez:
20
10
2023
Statut:
epublish
Résumé
The phase 3 QUEST (NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab 200/300 mg Unadjusted annualised severe exacerbation rates (AER) and change from parent study baseline (PSBL) in pre-bronchodilator forced expiratory volume in 1 s (FEV In all three groups, dupilumab treatment progressively reduced AER range to 0.17-0.30 during TRAVERSE (Weeks 48-96), increased pre-bronchodilator FEV For patients with uncontrolled, moderate-to-severe asthma with elevation of at least one type 2 biomarker, dupilumab treatment provides sustained, long-term reduction of exacerbation rates and improvements in lung function and asthma control irrespective of exacerbation history.
Sections du résumé
Background
UNASSIGNED
The phase 3 QUEST (NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab 200/300 mg
Patients and methods
UNASSIGNED
Unadjusted annualised severe exacerbation rates (AER) and change from parent study baseline (PSBL) in pre-bronchodilator forced expiratory volume in 1 s (FEV
Results
UNASSIGNED
In all three groups, dupilumab treatment progressively reduced AER range to 0.17-0.30 during TRAVERSE (Weeks 48-96), increased pre-bronchodilator FEV
Conclusion
UNASSIGNED
For patients with uncontrolled, moderate-to-severe asthma with elevation of at least one type 2 biomarker, dupilumab treatment provides sustained, long-term reduction of exacerbation rates and improvements in lung function and asthma control irrespective of exacerbation history.
Identifiants
pubmed: 37859672
doi: 10.1183/23120541.00037-2023
pii: 00037-2023
pmc: PMC10584079
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2023.
Déclaration de conflit d'intérêts
Conflict of interest: J. Corren reports research grants from and is a consultant for AstraZeneca, Genentech, Novartis, Regeneron Pharmaceuticals Inc. and Sanofi; and speaker fees from AstraZeneca, Genentech and Novartis. C.H. Katelaris is a Principal Investigator of the dupilumab asthma phase 2b (NCT01854047) and phase 3 (NCT02414854) studies for Regeneron Pharmaceuticals Inc. and Sanofi. M. Castro reports research support from the American Lung Association, AstraZeneca, GlaxoSmithKline, NIH, Novartis, PCORI, Pulmatrix, Sanofi-Aventis and Shionogi; is a consultant for Genentech, Novartis, Sanofi-Aventis and Teva; reports speaker fees from AstraZeneca, Genentech, GlaxoSmithKline, Regeneron Pharmaceuticals Inc., Sanofi and Teva; and royalties from Elsevier. J.F. Maspero is a consultant for AstraZeneca and Sanofi; reports speaker fees from GlaxoSmithKline, Menarini, Novartis and Uriach; and research grants from Novartis. M. Humbert reports consultant and speaker fees from AstraZeneca, Chiesi, GlaxoSmithKlein, Novartis and Sanofi. D.M.G. Halpin reports advisory board membership, speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Novartis, Pfizer, Sandoz and Sanofi. A. Altincatal, N. Pandit-Abid, J.A. Jacob-Nara and P.J. Rowe are employees of Sanofi, and may hold stock and/or stock options in the company. X. Soler, A. Radwan and Y. Deniz are employees and shareholders of Regeneron Pharmaceuticals Inc.
Références
Clin Transl Allergy. 2019 Aug 21;9:41
pubmed: 31452870
Respir Res. 2021 Oct 20;22(1):269
pubmed: 34670588
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5153-8
pubmed: 24706856
Am J Respir Crit Care Med. 2009 Jan 1;179(1):19-24
pubmed: 18990678
Allergol Int. 2017 Oct;66(4):568-573
pubmed: 28318883
Respir Med. 2007 Mar;101(3):481-9
pubmed: 16914299
Expert Rev Clin Immunol. 2017 May;13(5):425-437
pubmed: 28277826
Nat Rev Immunol. 2015 Jan;15(1):57-65
pubmed: 25534623
Eur Respir J. 2010 Dec;36(6):1410-6
pubmed: 20530041
J Allergy Clin Immunol. 2012 May;129(5):1229-35
pubmed: 22326484
Prim Care Respir J. 2007 Feb;16(1):22-7
pubmed: 17297523
Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5147-52
pubmed: 24706858
N Engl J Med. 2018 Jun 28;378(26):2486-2496
pubmed: 29782217
Allergy. 2020 May;75(5):1188-1204
pubmed: 31838750
Am J Respir Crit Care Med. 2017 Feb 1;195(3):302-313
pubmed: 27556234
Chest. 2001 Apr;119(4):1011-7
pubmed: 11296162
Lancet Respir Med. 2022 Jan;10(1):11-25
pubmed: 34597534
Eur Respir J. 2021 Oct 28;58(4):
pubmed: 34266940